Arcutis Biotherapeutics, Inc. (ARQT) Misses Q1 EPS by 3c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($1.31), $0.03 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance